Skip to main content
Clinical Trials/CTRI/2024/04/066244
CTRI/2024/04/066244
Not yet recruiting
Phase 1

Effect of supplementation of Amla (Emblica officinalis) in Honey on the hematological profile and iron homeostasis in anemic pregnancy: An open -labelled clinical trial.

JIPMER1 site in 1 country82 target enrollmentStarted: May 1, 2024Last updated:

Overview

Phase
Phase 1
Status
Not yet recruiting
Sponsor
JIPMER
Enrollment
82
Locations
1
Primary Endpoint
Hemoglobin level

Overview

Brief Summary

RESEARCH QUESTION

Does supplementation of Amla (Emblica officianalis) in anemic pregnant women improve their hematological profile and iron homeostasis

AIM

To assess the effect of supplementation of Amla (Emblica officianalis) in honey in anemic pregnant women on their hematological profile and indices of iron homeostasis

OBJECTIVES

PRIMARY

(1) Estimations of the hematological profile and indices of iron homeostasis before and after supplementation of Amla (Emblica officianalis) in a group of anemic pregnant women for a period of 45 days in addition to their regular iron supplementation.

(2) Estimations of the hematological profile and indices of iron homeostasis before and after 45 days of regular oral iron supplementation in another group of anemic pregnant women.

(3) Comparison of the changes in the hematological profile and iron homeostasis between the two groups after the 45 days of study

SECONDARY

(1) Assessment of the quality of life in anemic pregnant women in general and in relation to gastro intestinal disturbances, nausea and vomiting using standard questionnaires with and without Amla supplementation.

(2) Correlation analyses among indices of iron homeostasis, oxidative stress and inflammation.

METHODOLOGY

After the successful registration in CTRI Pregnant women with mild iron deficiency anemia on oral iron therapy visiting the Obstetrics and Gynecology department antenatal out patient clinic  meeting the inclusion and exclusion criteria will be recruited as the participants of the study

They will be divided into two groups by block randomization with stratification by convenient sampling method

Control group will be supplemented with usual oral iron therapy (60mg elemental iron three times a day) along with life style modifications which is advised by their treating doctor

Interventional group will be provided supplementation of two amla in honey (one in the morning and one in the night) every day for 45 days along with usual oral iron therapy (60mg elemental iron three times a day) and life style modifications which is advised by their treating doctor

The investigations including serum hepcidin, oxidative stress, serum ferritin and soluble transferrin receptor and hsCRP levels and hematological profile will be assayed before and after intervention along with their quality of life

The data will be statistically analysed

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 35.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • Hemoglobin level between 9 to 11 milligram per deciliter Age between 18 to 35 years 1st and 2nd trimester of pregnancy On oral iron therapy.

Exclusion Criteria

  • Patients with a history of anemia due to any other conditions like bleeding piles cardiac or renal or liver disorders Diabetes Mellitus Hypertension Pregnancy induced complications like hyperemesis gravidarum antepartum hemorrhage pre eclampsia eclampsia GDM jaundice Patients with a history of drug abuse Patients with a history of allergy to amla or honey.

Outcomes

Primary Outcomes

Hemoglobin level

Time Frame: 45 days

Hematological profile

Time Frame: 45 days

Indices of iron homeostasis

Time Frame: 45 days

Secondary Outcomes

  • Quality of life(45 days)

Investigators

Sponsor
JIPMER
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

SanthossiniS

JIPMER

Study Sites (1)

Loading locations...

Similar Trials